A medium-chain triglyceride containing ketogenic diet exacerbates cardiomyopathy in a CRISPR/Cas9 gene-edited rat model with Duchenne muscular dystrophy

被引:5
|
作者
Fujikura, Yuri [1 ]
Kimura, Koichi [2 ,3 ]
Yamanouchi, Keitaro [4 ]
Sugihara, Hidetoshi [4 ]
Hatakeyama, Masaki [5 ]
Zhuang, Haotong [1 ,8 ]
Abe, Tomoki [1 ]
Daimon, Masao [6 ]
Morita, Hiroyuki [6 ]
Komuro, Issei [6 ]
Oishi, Katsutaka [1 ,7 ,8 ,9 ]
机构
[1] Natl Inst Adv Ind Sci & Technol, Cellular & Mol Biotechnol Res Inst, Hlth Food Sci Res Grp, Ibaraki 3058566, Japan
[2] Univ Tokyo, Inst Med Sci, Dept Lab Med, Minato ku, Tokyo 1088639, Japan
[3] Univ Tokyo, Inst Med Sci, Dept Cardiol, Minato ku, Tokyo 1088639, Japan
[4] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo ku, Tokyo 1138657, Japan
[5] Miyagi Hlth Innovat, Sendai, Miyagi 9800021, Japan
[6] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo ku, Tokyo 1138655, Japan
[7] Tokyo Univ Sci, Grad Sch Sci & Technol, Dept Appl Biol Sci, Noda, Chiba, Japan
[8] Univ Tokyo, Grad Sch Frontier Sci, Dept Computat Biol & Med Sci, Kashiwa, Chiba, Japan
[9] Univ Tsukuba, Sch Integrat & Global Majors SIGMA, Ibaraki, Japan
关键词
CARDIAC-HYPERTROPHY; SKELETAL; ACID;
D O I
10.1038/s41598-022-15934-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Duchenne muscular dystrophy (DMD) is an X-linked recessive myopathy caused by dystrophin mutations. Although respiratory management has improved the prognosis of patients with DMD, inevitable progressive cardiomyopathy is a current leading cause of premature death. Recently, we showed that a medium-chain triglyceride containing ketogenic diet (MCTKD) improves skeletal muscle function and pathology in a CRISPR/Cas9 gene-edited rat model with DMD. In this study, we sought to clarify whether MCTKD also improves the cardiomyopathy in these rats. DMD rats were fed either the MCTKD or normal diet (ND) from ages of 3 weeks to 9 months old. Compared with the ND-fed rats, MCTKD-fed rats showed significantly prolonged QRS duration, decreased left ventricular fractional shortening, an increased heart weight/body weight ratio, and progression of cardiac fibrosis. In contrast to our previous study which found that MCTKD improved skeletal myopathy, the current study showed unexpected exacerbation of the cardiomyopathy. Further studies are needed to explore the underlying mechanisms for these differences and to explore modified dietary options that improve skeletal and cardiac muscles simultaneously.
引用
收藏
页数:9
相关论文
共 38 条
  • [21] Delivery of a Multiplex CRISPR/Cas9 Machinery for the Treatment of Duchenne Muscular Dystrophy with One Single Gene Deleted Adenoviral Vector
    Ehrke-Schulz, Eric
    Mouly, Vincent
    Kley, Rudolph A.
    Ehrhardt, Anja
    MOLECULAR THERAPY, 2018, 26 (05) : 329 - 330
  • [22] Delivery of a multiplex CRISPR/Cas9 machinery for the treatment of Duchenne muscular dystrophy with one single gene deleted adenoviral vector
    Ehrke-Schulz, E.
    Mouly, V.
    Kley, R. A.
    Ehrhardt, A.
    HUMAN GENE THERAPY, 2017, 28 (12) : A40 - A40
  • [23] Delivery of CRISPR/Cas9 via Viral and Non-Viral Methods to Reframe the DMD Gene in a Humanized Mouse Model of Duchenne Muscular Dystrophy
    Young, Courtney S.
    Ji, Ying
    Liu, Xiangsheng
    Mokhonova, Ekaterina
    Emami, Michael
    Bengtsson, Niclas
    Chamberlain, Jeffrey S.
    Pyle, April D.
    Meng, Huan
    Spencer, Melissa J.
    MOLECULAR THERAPY, 2018, 26 (05) : 396 - 396
  • [24] Correction of a common Duchenne muscular dystrophy mutation by CRISPR/Cas9 gene editing using homology-independent targeted integration
    Nicolau, S.
    Sarff, J.
    Vetter, T.
    Stephenson, A.
    Flanigan, K.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [25] Dystrophin Restoration in a Humanized Mouse Model of Duchenne Muscular Dystrophy by Gene Editing with S. Aureus Cas9
    Robinson-Hamm, Jacqueline N.
    Nelson, Christopher E.
    Gemberling, Matthew
    Gough, Veronica
    Rivera, Ruth M. Castellanos
    Aartsma-Rus, Annemieke
    Asokan, Aravind
    Gersbach, Charles A.
    MOLECULAR THERAPY, 2018, 26 (05) : 118 - 119
  • [26] Dystrophin Restoration in a Humanized Mouse Model of Duchenne Muscular Dystrophy by Gene Editing with S. aureus Cas9
    Robinson-Hamm, Jacqueline N.
    Nelson, Christopher E.
    Gemberling, Matthew
    Rivera, Ruth M. Castellanos
    Aartsma-Rus, Annemieke
    Asokan, Aravind
    Gersbach, Charles A.
    MOLECULAR THERAPY, 2017, 25 (05) : 17 - 17
  • [27] Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy (vol 8, 14454, 2017)
    Bengtsson, Niclas E.
    Hall, John K.
    Odom, Guy L.
    Phelps, Michael P.
    Andrus, Colin R.
    Hawkins, R. David
    Hauschka, Stephen D.
    Chamberlain, Joel R.
    Chamberlain, Jeffrey S.
    NATURE COMMUNICATIONS, 2017, 8
  • [28] A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing
    Zhang, Yu
    Li, Hui
    Nishiyama, Takahiko
    McAnally, John R.
    Sanchez-Ortiz, Efrain
    Huang, Jian
    Mammen, Pradeep P. A.
    Bassel-Duby, Rhonda
    Olson, Eric N.
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2022, 29 : 525 - 537
  • [29] A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing
    Zhang, Yu
    Li, Hui
    Nishiyama, Takahiko
    McAnally, John R.
    Sanchez-Ortiz, Efrain
    Huang, Jian
    Mammen, Pradeep P. A.
    Bassel-Duby, Rhonda
    Olson, Eric N.
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2022, 29 : 525 - 537
  • [30] CRISPR/Cas9-Mediated Gene-Editing Rescues Dystrophin Expression in a Dog Model of Duchenne Muscular Dystrophy
    Maruyama, Rika
    Quynh Nguyen
    Aoki, Yoshitsugu
    Takeda, Shin'ichi
    Yokota, Toshifumi
    MOLECULAR THERAPY, 2018, 26 (05) : 121 - 121